JB
ELVN icon

Julian Baker’s Enliven Therapeutics ELVN Stock Holding History

Julian Baker’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.9M Hold
905,191
– – 0.23% 39
2026
Q1 		$35.5M Buy
905,191
+633,785
+234% +$17.6M 0.2% 41
2025
Q4 		$4.18M Buy
271,406
+156,573
+136% +$3.12M 0.02% 76
2025
Q3 		$2.35M Hold
114,833
– – 0.02% 80
2025
Q2 		$2.3M Hold
114,833
– – 0.02% 74
2025
Q1 		$2.26M Hold
114,833
– – 0.03% 74
2024
Q4 		$2.58M Hold
114,833
– – 0.03% 81
2024
Q3 		$2.93M Hold
114,833
– – 0.03% 77
2024
Q2 		$2.68M Hold
114,833
– – 0.03% 76
2024
Q1 		$2.02M Buy
+114,833
New +$1.76M 0.03% 75

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Julian Baker's ELVN Position: Q2 2026 in Review

Julian Baker held its Enliven Therapeutics (ELVN) position steady in Q2 2026 at 905,191 shares worth $45.9M. The position accounts for 0.23% of the portfolio, ranked #39.

Julian Baker first reported a position in ELVN in Q1 2024 and has held it in 10 quarters since. 209 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Julian Baker held 905,191 shares of Enliven Therapeutics worth $45.9M as of Q2 2026.
  • Julian Baker left its Enliven Therapeutics share count unchanged in Q2 2026.
  • Enliven Therapeutics made up 0.23% of Julian Baker's portfolio in Q2 2026, its #39 holding.
  • Julian Baker first reported a position in Enliven Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 209 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Baker Bros. Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.